ecteinascidin 743 has been researched along with mtt formazan in 1 studies
| Studies (ecteinascidin 743) | Trials (ecteinascidin 743) | Recent Studies (post-2010) (ecteinascidin 743) | Studies (mtt formazan) | Trials (mtt formazan) | Recent Studies (post-2010) (mtt formazan) |
|---|---|---|---|---|---|
| 660 | 102 | 404 | 690 | 1 | 136 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldwasser, F; Kohlhagen, G; Pommier, Y; Takebayashi, Y; Urasaki, Y | 1 |
1 other study(ies) available for ecteinascidin 743 and mtt formazan
| Article | Year |
|---|---|
Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Topics: Antineoplastic Agents, Alkylating; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Dioxoles; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; Formazans; Humans; Immunoenzyme Techniques; Isoquinolines; Proliferating Cell Nuclear Antigen; Tetrahydroisoquinolines; Tetrazolium Salts; Trabectedin; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |